See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/328913716

Metadichol ® a Novel Agonist of the Anti-aging Klotho Gene in Cancer Cell Lines

Article in Journal of Cancer Science and Therapy · November 2018

DOI: 10.4172/19485956.1000567

CITATIONS		READS
0		153
1 author	:	
0	Palayakotai R Raghavan	
E.	Nanorx Inc	
	62 PUBLICATIONS 381 CITATIONS	
	SEE PROFILE	
Some of	the authors of this publication are also working on these related projects:	

Project Metadichol View project

Metadichol and skin diseases View project



Research Article

Metadichol[®] a Novel Agonist of the Anti-aging Klotho Gene in Cancer Cell Lines

Palayakotai R Raghavan*

Nanorx Inc., PO Box 131, Chappaqua, NY 10514, USA

Abstract

Klotho is an anti-aging protein that is mostly secreted by the kidneys, the brain, and the thyroid. It plays a significant role in regulating kidney function and vascular health. Klotho gene is named after "the Spinner" (Clotho from Greek mythology), the goddess who spins the thread of life. Klotho is a transmembrane protein known to be a co-receptor for Fibroblast Growth Factor-23. Klotho gene is expressed in a variety of tissues changes in the levels are associated with many diseases. Klotho is a tumor suppressor in breast cancer and its expression is reduced in human pancreatic adenocarcinoma, and treatment with klotho inhibits the growth of pancreatic cancer cells *in vitro* and *in vivo*.

Growing evidence suggests that an increase in KL expression may be beneficial for age-related diseases such as arteriosclerosis and diabetes. It remains a challenge today to induce Klotho expression. Herein we show that treating pancreatic cancer cells PANC1, MIAPACA and COLO-205 with Metadichol® a novel food based lipid emulsion of long chain alcohols at picogram/ml, concentration led to a 4-10 fold increase in Klotho expression as seen quantitative RT-PCR. These results suggest the use of Metadichol® given its constituents that are present in foods we consume every day is a novel therapeutic intervention for pancreatic cancer and other diseases.

Keywords: VDR; Metadichol; Klotho; Inverse agonist; Protean agonist; Constitutive receptors; Pancreatic cancer; FGF-23; Diabetes; Anti-aging; PANC1; COLO-205; MIAPACA; Long chain alcohols

Introduction

The Greek goddess whose name is associated with Klotho protein spins life's thread and is associated with reversing aging in mammals. In Greek Mythology, Klotho has two siblings, Lachesis and Atropos, and one determines the length of the thread of life and the other cuts the thread. Klotho (KL), which was named after one of the three goddesses of fate who controlled aging in Greek mythology, was initially identified in 1997 as the gene responsible for early aging-like symptoms in mice [1], and in several other tissues [2]. It acts as a coreceptor with fibroblast growth factor receptor-1 (FGFR1)to bind fibroblast growth factor 23 (FGF23) and mediate phosphaturia to correct the hyperphosphatemia arising from 1,25-dihydroxy vitamin D (calcitriol or 1,25D) Stimulation of intestinal calcium and phosphate absorption.1,25D regulates the expression of both membrane and soluble klotho forms in multiple kidney cell types to support FGF23 phosphaturic and vitamin D counter-regulatory actions at the kidney, possibly exerting antiaging effects [3].

The observation that Klotho inhibits insulin/IGF-1 signalling has ramifications for therapeutic intervention in cancer as well. Activation of the IGF receptor has been implicated in the etiology of carcinomas [4]. There is a growing body of evidence implicating Klotho as a tumour suppressor [5]. In particular cervical, colorectal, gastric and lung carcinoma, pancreatic, hepatocellular carcinoma and breast cancer amongst a few [6]. In general, Higher Klotho expression was associated with smaller tumor size and Klotho treatment slowed the progression of cancer. Klotho is significantly down regulated in all cancer types including brain malignancies [7]. Down regulation of Klotho (Table 1) was observed across the different cancer types. The role of Klotho in cancer as a tumor suppressor mentioned by Wolf I [8] showed how Klotho putative tumor suppressor in breast cancer.

The available data indicate that Klotho acts as a universal tumor suppressor and that there may be a role for Klotho cancer treatment. Currently, there are no Klotho-based treatments available, although a number of commonly used compounds do either directly up-regulate Klotho *in vitro*, like PPAR γ agonists [9], vitamin D [10], Testosterone [11] and Resveratrol [12], or otherwise up-regulate or at least inhibit down-regulation of Klotho *in vivo*. Recent data indicate that Klotho has extensive effects over the entire spectrum of human diseases [13] as shown in Table 1.

Acetylcholine and Nitric Oxide Dysregulation Aging (highly accelerated)	Bone Loss (such as osteoporosis and low bone mass)				
All-cause mortality	Cancer				
Anemia	Cataracts				
Anorexia	Chronic stress				
Atherosclerosis (as well as calcification of the arteries)	Depression				
Growth hormone deficiency	Diabetes				
Kidney disease (such as CKD and electrolyte imbalances) Kidney transplant	Glaucoma				
Hyperphosphatemia	Multiple system atrophy				
Hyperparathyroidism	Pseudoexfoliation syndrome				
Hypertension	Rheumatoid arthritis				
Impaired cognition (such as Alzheimer's Disease)	Sarcopenia				
Inflammatory bowel disease	Skin atrophy (such as scleroderma)				
Lung damage	Vascular disease (such as coronary artery disease)				
Stroke					

Table 1: Klotho effects over the entire spectrum of human diseases

*Corresponding author: Palayakotai R Raghavan, Nanorx Inc., PO Box 131, Chappaqua, NY 10514, USA, Tel: +1-914-671-0224; E-mail: raghavan@nanorxinc.com

Received October 11, 2018; Accepted November 08, 2018; Published November 10, 2018

Citation: Raghavan PR (2018) Metadichol® a Novel Agonist of the Anti-aging Klotho Gene in Cancer Cell Lines. J Cancer Sci Ther 10: 351-357. doi: 10.4172/1948-5956.1000567

Copyright: © 2018 Raghavan PR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Klotho levels are decreased in certain types of human tumor cells/ tissues, and reduced levels are associated with decreased survival [14]. Animal studies show that Klotho can improve survival rates [15] reduce metastasis and reduce cancer cell resistance to chemotherapeutic agents [16]. Abramovitz [17] showed in studies on pancreatic adenocarcinoma cell lines that Klotho expression is reduced, and treatment with Klotho effectively slows growth of pancreatic cancer cells *in vitro* and *in vivo*. Biao Xie also have shown that Klotho is a tumor suppressor in gastric cancer [18]. Injection of secreted Klotho protein suppressed metastasis and improved survival in mice transplanted with human lung cancer cells [19]. Long-term administration of KL to mice shows a favorable toxicity profile. As klotho is an endogenous hormone, its administration is potentially feasible and may serve as a novel therapy for pancreatic, as well as other cancers.

Metadichol^{*} nano-emulsion of long chain alcohols is an inverse agonist of VDR (Vitamin D receptor) that is non- toxic. We tested it in the pancreatic cell lines PANC1, COLO-205 and MIAPACA cell lines and the results show that it enhances Klotho expression and thus would pave the way for use a therapeutic in diseases where increased Klotho levels are required.

Experimental

The experimental work was outsourced and carried out by Skanda Life Sciences Private Limited of Bangalore India. The cell lines were purchased from ATCC, USA and primers from Eurofins India. PCR and qPCR Method Standardization. For each of target gene the PCR conditions viz, Tm, Amplicon specificity & size were optimized using in-house established and validated methods/reagents.

qPCR

Instruments used CFX96 real time PCR, Bio-Rad. Gene regulation of KLOTHO genes in MiaPaca, Colo-205, Panc-1 cells treated with metadichol.

Cell lines

COLO 205 (ATCC° CCL-222^m), MIA PaCa-2 (ATCC° CRL-1420^m), PANC-1 (ATCC° CRL-1469^m) (Table 2).

Sample Preparation and RNA Isolation

Total RNA from the cells was extracted using TRizol Reagent (Invitrogen) according to manufacturer's instruction. Cells were washed twice with PBS and centrifuged at 2000rpm for 5min. To the cell pellet, 1ml of TRIzol (per p35 dish) was added in 1.5ml Eppendrof

tube and vortexed. Samples were allowed to stand for 5 minutes at room temperature. To the reaction mixture 0.2 ml of chloroform is added and vigorously mixed for 15 seconds. The tube was allowed to stand at room temperature for 5 minutes, centrifuged the resulting mixture at 10,000 rpm for 15min at 4° C. Upper aqueous phase is transferred to a new clean Eppendorf tube and treated with 0.5ml of isopropanol. The resultant mixture is mixed gently by inverting the sample 5 times and incubated at room temperature for 5 minutes. Samples were centrifuged at 10,000 rpm for 10 minutes at 4° C. Supernatant liquid was discarded and the RNA pellet was washed by adding 1ml of 70% ethanol. Mix the sample gently by inverting few times. Centrifuged for 5min at 14,000 rpm at 4° C. Supernatant was discarded by inverting the tube on a clean tissue paper. Later, the pellet was dried by incubating in a dry bath for 5min at 55° C. The pellet was then resuspended in 25 µl of DEPC treated water.

RT-PCR

A semi quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was carried out using Techno Prime system to determine the levels of Klotho and β -Actin mRNA expressions. The cDNA was synthesized from 2 µg of RNA using the Verso cDNA synthesis kit (Thermo Fischer Scientific) with oligo dT primer according to the manufacturer's instructions. The reaction volume was set to 20µl and cDNA synthesis was performed at 42° C for 60 min, followed by RT inactivation at 85° C for 5 min (Table 3).

PCR

The PCR mixture (final volume of 20 µL) contained 1 µL of cDNA, 10 μL of Red Taq Master Mix 2x (Amplicon) and 1 μM of each complementary primer specific for Klotho and β -Actin (internal control) sequence. The samples were denatured at 94°C for 5 minutes and amplified using 35 cycles of 94° C for 30 seconds, 53° C for 30 seconds, and 72° C for 1 minute for KLOTHO renaturation was set to 49° C and for β -Actin the renaturation was set to 55° C for 30 seconds followed by a final elongation at 72° C for 10 minutes. The optimal numbers of cycles have been selected for amplification of this genes experimentally so that amplifications were in the exponential range and had not reached a plateau. Ten microliters of the final amplification product were run on a 2% ethidium-stained agarose gel and photographed. Quantification of the results was accomplished by measuring the optical density of the bands, using the computerized imaging program Image J. The values were normalized to β-Actin intensity levels (Figure 1-10).

Sample	Cell culture condition	Treatment
		Control (Media)
		1 pg/ml
Matadiabal	MIAPACA COLO-205, PANC-1 cells	100 pg/ml
Metadicitor	(1 × 10 ⁶) grown in P35 dish were treated with test compound	1 ng/ml
		100 ng/ml
		1 µg/ml

Table 2: Treatment protocol.

Gene	Primer pair	Sequence	Tm	Product size (bp)
D. A atin	FP	TCCTCCTGAGCGCAAGTACTCT	62.1	150
B-ACUIT	RP	GCTCAGTAACAGTCCGCCTAGAA	62.4	155
Klotho	FP	GGGAGGTCAGGTGTCCATTG	55.88	150
KIOLIIO	RP	TGCTCTCGGGATAGTCACCA	53.83	102



Citation: Raghavan PR (2018) Metadichol® a Novel Agonist of the Anti-aging Klotho Gene in Cancer Cell Lines. J Cancer Sci Ther 10: 351-357. doi: 10.4172/1948-5956.1000567



Figure 1: Amplification of β-Actin gene in MIAPACA (Lane 1-Ladder; Lane 2-Control; Lane 3-1 pg/mL; Lane 4-100 pg/mL; Lane 5-1 ng/ml; Lane 6-100 ng/ml; Lane 7-1 µg/mL).



Figure 2: Amplification of Klotho gene in MIAPACA cell (Lane 1-Ladder; Lane 2-Control; Lane 3-1 pg/mL; Lane 4-100 pg/mL; Lane 5-1 ng/ml; Lane 6-100 ng/ml; Lane 7-1 µg/mL).



Lane /-1 µg/mL).

Citation: Raghavan PR (2018) Metadichol® a Novel Agonist of the Anti-aging Klotho Gene in Cancer Cell Lines. J Cancer Sci Ther 10: 351-357. doi: 10.4172/1948-5956.1000567



Figure 4: Amplification of Klotho gene in COLO-205 cell (Lane 1- Ladder; Lane 2-Control; Lane 3-1 ng/mL; Lane 4-100 ng/mL; Lane 5-1 pg/ml; Lane 6-100 pg/ml; Lane 7-1 µg/mL).



Figure 5: Amplification of β-Actin gene in PANC1 (Lane 1- Ladder; Lane 2-Control; Lane 3-1 ng/mL; Lane 4-100 ng/mL; Lane 5-1 pg/ml; Lane 6-100 pg/ml; Lane 7-1 µg/mL).



J Cancer Sci Ther, an open access journal ISSN: 1948-5956

Image Core Spresse France Corresse Solution Core Core <thcore< th=""> <thcore< th=""> <thcore< th=""></thcore<></thcore<></thcore<>						CFX96 softwar	e calculated data	format			2					
Rate Cons * Log Object State Log Alt No State Log Alt State State Log Alt State State </th <th>Target</th> <th>Sample</th> <th>Ctrl</th> <th>Expression</th> <th>Expression SEM</th> <th>Corrected Expression SEM</th> <th>Mean Cq</th> <th>Cq SEM</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	Target	Sample	Ctrl	Expression	Expression SEM	Corrected Expression SEM	Mean Cq	Cq SEM								
Nome Nome Nome Nome Nome Nome Nome Nome	Klotho	Control	*	1.000	0.025	0.025	31.330	0.074								
Note bills Note bills Order 1982 Order 1983 Order 1983 <thorder 1983 Order 1983 Order 19</thorder 	Klothe	lpg		10.339	0.301	0,301	26.760	0.403							-	
Data Units Units <thu< td=""><td>Klotho</td><td>Ino</td><td>÷</td><td>4 595</td><td>0.095</td><td>0.095</td><td>27.340</td><td>0.028</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></thu<>	Klotho	Ino	÷	4 595	0.095	0.095	27.340	0.028								
Kank Image Image <th< td=""><td>Klotho</td><td>100ng</td><td>B) - 1</td><td>1.932</td><td>0.007</td><td>0.007</td><td>29,250</td><td>0.023</td><td></td><td>-</td><td>-</td><td></td><td></td><td></td><td></td><td></td></th<>	Klotho	100ng	B) - 1	1.932	0.007	0.007	29,250	0.023		-	-					
And Const N No. No. </td <td>Klotho</td> <td>lug</td> <td>8</td> <td>1.526</td> <td>0.004</td> <td>0.004</td> <td>29.670</td> <td>0.015</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Klotho	lug	8	1.526	0.004	0.004	29.670	0.015								
Adm Const. NA NA </td <td></td> <td></td> <td></td> <td></td> <td></td> <td><u>1</u></td> <td>- i</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						<u>1</u>	- i									
Arm Ing NA N	Actin	Control	*	N/A	N/A	N/A	19.470	0.359								
Altern Image NA	Actin	Ipg	e	N/A	N/A	N/A	18.270	0.161								
Active Image NA SA	Actin	loopg	ê	N/A N/A	N/A N/A	N/A N/A	18.510	0.172								
Active Inde Vex Vex NA 10.60 0.015 File Free Fr	Actin	100ng	s	N/A N/A	N/A N/A	N/A N/A	17.830	0.048								
Norm Norm <th< td=""><td>Actin</td><td>lug</td><td>8</td><td>N/A</td><td>N/A</td><td>N/A</td><td>18.420</td><td>0.038</td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>1</td><td></td></th<>	Actin	lug	8	N/A	N/A	N/A	18.420	0.038						1	1	
First Test Cented Test Cented Test SYR8 Kloin Usinews 13 Conell 75.5 1															-	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Fluor	Target	Content	Treatment	Melt Temp										
Style Linke Usaces 3 Control 295 Style Kide Usaces 3 Control 775 Style Kide Usaces 3 Ipg 775 Style Kide Usaces 3 Ipg 775 Style Kide Usaces 3 Ipg 775 Style Kide Usaces 3 Ibg 777 Style Kide Usaces 3 Ibg 775 Style Kide Usaces 3 Ibg 775 Style Kide Usaces 3 Ibg 755 Style Kide		SYBR	Klotho	Unknown-13	Control	76.5										
$ \begin{array}{ c $		SYBR	Klotho	Unknown-13 Unknown-21	Control	76.5										
SYRE Kide Ublames H Ipp 77 SYRE Ads Ublames J Ipp 77 SYRE Ads Ublames J Ipp 775 SYRE Kide Ublames J Ipp 775 SYRE Ads Ublames J Ipp 775 SYRE Kide No No No SYRE Kide No <t< td=""><td></td><td>SYBR</td><td>Actin</td><td>Unknown-31</td><td>Control</td><td>77.5</td><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		SYBR	Actin	Unknown-31	Control	77.5				-						
STRE Linke Ubases-14 $\frac{1}{12}$ 77 STRE Aam Ubases-30 $\frac{1}{12}$ 77 STRE Aam Ubases-30 $\frac{1}{12}$ 77 STRE Aam Ubases-30 $\frac{1}{12}$ 77 STRE Aam Ubases-31 $\frac{1}{102}$ 77 STRE Aam Ubases-31 $\frac{1}{102}$ 77 STRE Linke Ubases-31 $\frac{1}{102}$ 75 STRE Linke Ubases-31 $\frac{1}{102}$ 75 STRE Linke Ubases-31 $\frac{1}{102}$ 75 STRE Aam Ubases-31 $\frac{1}{102}$ 75 75 STRE Aam <td></td> <td>SYBR</td> <td>Klotho</td> <td>Unknown-14</td> <td>lpg</td> <td>77.5</td> <td></td>		SYBR	Klotho	Unknown-14	lpg	77.5										
SYBR Acta Using solution 20 Ipg 77.5 SYBR Kolo Using solution 23 Ipg 77.5 SYBR Kolo Using solution 23 Ipg 77.5 SYBR Kolo Using solution 23 Ipg 77.5 SYBR Acta Using solution 23 Ipg 77.5 SYBR Acta Using solution 23 Ipg 77.5 SYBR Acta Using solution 24 Ipg 77.5 SYBR Kolo Using solution 27 Ibling 77.5 SYBR Kolo </td <td></td> <td>SYBR</td> <td>Klotho</td> <td>Unknown-14</td> <td>lpg</td> <td>77</td> <td></td> <td>V</td> <td>Amplifica</td> <td>tion Profile of KI</td> <td>otho(Green) & A</td> <td>ctin(Red) in Mia</td> <td>apaca cell line</td> <td></td> <td></td> <td></td>		SYBR	Klotho	Unknown-14	lpg	77		V	Amplifica	tion Profile of KI	otho(Green) & A	ctin(Red) in Mia	apaca cell line			
NYRE Actu Unizona 32 ipg 773 SYRE Kofu Unizona 13 Blögu 77 SYRE Kofu Unizona 14 Brogu 77 SYRE Kofu Unizona 14 Brogu 75 SYRE Kofu Unizona 14 Brogu 75 SYRE Kofu Unizona 31 Brogu 75 SYRE Kofu Kofu Brogu NA SYRE Kofu Kofu Brogu NA SYRE Kofu		SYBR	Actin	Unknown-32	lpg	77.5	200	0							-	
SYRE Lotto Outcome::::::::::::::::::::::::::::::::::::		SYBR	Actin	Unknown-32	lpg	77.5		1			1			7	-	-
SYRE View View <th< td=""><td></td><td>SYBR</td><td>Klothe</td><td>Unknown-15</td><td>100pg</td><td>17</td><td>100</td><td>. I</td><td></td><td></td><td>1</td><td></td><td>1</td><td>1/</td><td></td><td>-</td></th<>		SYBR	Klothe	Unknown-15	100pg	17	100	. I			1		1	1/		-
VYRR Adva Ubiason-30 UDig reg 77.2 SYRR Kobb Ubiason-30 Ing 76.5 SYRR Kobb Ubiason-30 Ing 76.5 SYRR Actin Diason-34 Ing 77.5 SYRR Actin Diason-34 Ing 77.5 SYRR Actin Diason-34 Ing 77.5 SYRR Actin Diason-36 Ing 77.5 SYRR Actin Diason-36 Ing 77.5 SYRR Kobb Diason-36 Ing 77.5 SYRR Kobb Diason-36 Ing 77.5 SYRR Kobb No 77.5 Cycles SYRR Kobb No 77.5 Cycles Cycles SYRR Actin No 77.5 Cycles Cycles SYRR Actin No No No No SYRR Actin No Tratinest Cq		SYBR	Actin	Unknown-33	100pg	77	150	" I						///		-
SYRE Kabo Usacon-10 Ing 7782 SYRE Actio Usacon-30 Ing 776 SYRE Koto Usacon-34 Ing 77 SYRE Koto Usacon-34 Ing 77.5 SYRE Koto Usacon-36 Ing 77.5 SYRE Koto Usacon-36 Ing 77.5 SYRE Koto Usacon-36 Ing 77.5 SYRE Koto No require como NA No SYRE <td< td=""><td></td><td>SYBR</td><td>Actin</td><td>Unknown-33</td><td>100pg</td><td>77</td><td></td><td>1</td><td></td><td></td><td>2</td><td></td><td>1</td><td>1</td><td>4</td><td>1 -</td></td<>		SYBR	Actin	Unknown-33	100pg	77		1			2		1	1	4	1 -
SYRE Kutho Ubianon-16 Ing 77 SYRE Actin Disanon-16 Ing 77 SYRE Actin Disanon-17 Ib0g 76.5 SYRE Kobb Disanon-18 Iug 76.5 SYRE Kobb Disanon-36 Iug 77.5 SYRE Kobb Nobb Trinson-36 Iug 77.6 SYRE Kobb Nobb Transon-36 Iug 77.6 SYRE		SYBR	Klotho	Unknown-16	Ing	76.5	100 PH	0 +					the second	FA	-	
State Atta Utilization Utiliz		SYBR	Klotho	Unknown-16	Ing	76.5		ŧ			4	1	-	The	-	1 _
SYBR Action Uninsense 7: (Minores 17: 978) Uningent 7: (Minores 18: 100; 978) Uninsense 7: 100; 978 Uninsense 7: 100; 9775 Uninsense 7: 100; 9775 </td <td></td> <td>SYBR</td> <td>Actin</td> <td>Unknown-34</td> <td>Ing</td> <td>77</td> <td> 50</td> <td>o 1</td> <td></td> <td>\</td> <td></td> <td></td> <td>1.11</td> <td>No.</td> <td></td> <td>- 1</td>		SYBR	Actin	Unknown-34	Ing	77	50	o 1		\			1.11	No.		- 1
SYBB Kinds Utilizeen:15 Oting 785 SYBB Anfit Utilizeen:35 IOD 725 SYBR Kinds Utilizeen:35 IOD 75 SYBR Kinds Utilizeen:35 IUg 76.5 SYBR Kinds Utilizeen:36 IUg 77.5 SYBR Anii Utilizeen:36 IUg 77.5 SYBR Kinds Utilizeen:36 IUg 77.5 SYBR Kinds Nonew:36 IUg 77.5 SYBR Kinds Nonew:36 IUg 77.5 SYBR Kinds Nonepide control NA SYBR Kinds No incpide control NA SYBR Kinds Utilizecontrol NA SYBR Kords Control 27.54 26.76 0.573 11.36 0 1.00 Unizeen:16 Ing 27.34 27.69 0.664 9.65 -2.2 4.59 Unizeen:17		SYBR	Klotho	Unknown-34 Unknown-17	100ng	76.5		Ŧ			/		1.11	1	3	
SYBR Adit Ubinswei-35 100g 77 10 20 50 60 70 70 70		SYBR	Klotho	Unknown-17	100ng	76.5		0							-	-
SYBR Addit Unknow-16 Uig 775 10 20 20 50 40 SYBR Kilob Unknow-18 Uig 765		SYBR	Actin	Unknown-35	100ng	77									-	
SYRB Kuba Unknown-18 Lug 76.5 SYRB Acin Unknown-38 Lug 77.5 SYRB Acin Unknown-38 Lug 77.5 SYRB Acin Unknown-38 Lug 77.5 SYRB Koto No implace control NA SYRB Koto No implace control NA SYRB Acin No implace control NA SYRB Target Castent Terame Cq Acin Cq Meas Cq Std. Dec Delta Cq Delta Cq Aid change Unknown-13 Control 27.35 27.36 0.042 8.83 <td< td=""><td></td><td>SYBR</td><td>Actin</td><td>Unknown-35</td><td>100ng</td><td>77.5</td><td></td><td>ò</td><td>1</td><td>D</td><td>20</td><td></td><td>30</td><td></td><td>40</td><td></td></td<>		SYBR	Actin	Unknown-35	100ng	77.5		ò	1	D	20		30		40	
SYBR Kein Uninove-36 Ling PR3 SYBR Acin Uninove-36 Ling 77.5 SYBR Kein Witinove-36 Ling 77.5 SYBR Kein Witinove-36 Ling 77.5 SYBR Kein Witinove-36 Ling 77.5 SYBR Kein Witinove-37 NA NA SYBR Acin Witinove-10 NA SYBR Acin Witinove-13 Control NA SYBR Acin Witinove-13 Control 27.55 26.76 0.573 11.86 0 1.00 Fine Target Castest Treamest 27.31 27.34 0.042 8.83 -3.03 K17 Uninove-16 Ing 27.33 27.34 0.042 8.83 -3.03 K17 Uninove-17 100ng 27.34 27.49 0.042 8.83 -3.03 K17 Uninove-10 Ing 27.34 </td <td></td> <td>SYBR</td> <td>Klotho</td> <td>Unknown-18</td> <td>lug</td> <td>76.5</td> <td></td> <td></td> <td></td> <td></td> <td>Cycles</td> <td>4</td> <td></td> <td></td> <td></td> <td></td>		SYBR	Klotho	Unknown-18	lug	76.5					Cycles	4				
SYBR Action Ubiasewn-36 Fug 77.5 No No <td></td> <td>SYBR</td> <td>Actin</td> <td>Unknown-18 Unknown 36</td> <td>lug</td> <td>76.5</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td>-</td> <td></td>		SYBR	Actin	Unknown-18 Unknown 36	lug	76.5								-	-	
SYBR Kulm No lengistic control NA SYBR Adm No lengistic control NA Manual Control 221.6 0.473 11.66 0 1.00 Unknown-14 1pg 31.4 31.33 0.016 8.49 -3.37 10.34 Unknown-15 100pg 27.37 27.34 0.42 8.83 -3.03 8.17 Unknown-17 100ng 29.69 0.064 9.66		SYBR	Actin	Unknown-36	Ing	77.5									-	
SYBR Kolo No Emplace control NA SYBR Actin No Emplace control NA Manness Control Cq Cq Mona Cq Std. Dec Delta Cct Delta Delta Fold change Uninnown-14 Ipg 31.35 20.45 0.957 10.34 0.100 0.064 3.03 8.17 0.04 0.059 1.031 0.04 0.059 1.031 0.04 0.059 1.031 0.04 0.059 1.031 0.04 0.059 1.031 0.04 0.059 1.031 0.04 0.059 1.051 0.051 </td <td></td> <td>SYBR</td> <td>Klotho</td> <td>No Template control</td> <td></td> <td>NA</td> <td></td>		SYBR	Klotho	No Template control		NA										
SYBR Actin No Template control NA YYBR Actin No Template control NA NA NA YYBR Actin No Template control NA NA NA NA YYBR Actin No Template control NA NA NA NA NA NA YBR Actin No Template control NA NA <t< td=""><td></td><td>SYBR</td><td>Klotho</td><td>No Template control</td><td>С.</td><td>NA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		SYBR	Klotho	No Template control	С.	NA										
SYBR Actia Notemplate control NA Image: control i		SYBR	Actin	No Template control	8	NA					· · · · · · · · · · · · · · · · · · ·					
Image: state in the s		SYBR	Actin	No Template control	<u>C</u>	NA					-					
First Target Content Terment Cq Manu Leilared data Lermat Optime Cq Pold hange Fold hange Image: SyBR First Content Terment Cq Mean Cq Mean Cq Std. Dec Delta Cq Fold hange Image: SyBR Fold hange Image: SyBR Unknown-13 Control 26.76 0.573 11.86 0 1.00 Image: SyBR Image: SyBR Image: SyBR Image: SyBR Image: SyBR Image: SyBR 100pg 27.31 27.34 0.042 8.83 3.03 8.17 Image: SyBR Image: SyBR Image: SyBR Image: SyBR Image: SyBR 27.93 27.44 0.042 8.83 3.03 8.17 Image: SyBR Image: SyBR Image: SyBR Image: SyBR Image: SyBR Image: SyBR 27.93 27.49 0.064 9.66 2.22 4.59 Image: SyBR																
Flue Target Content Treatment Cq Cq Man Cq Std. Pe Defta Cq O_{CQ} Fold change O_{CQ}						Manua	calculated data	format		Delta Delta					0	
SYBR Klown-13 Control 27.16 26.55 26.76 0.573 11.86 0 1.09 SYBR Inknown-14 1pg 31.4 31.25 31.33 0.066 8.49 -3.37 10.34 Unknown-15 100pg 27.31 27.37 27.34 0.042 8.83 -3.03 8.17 3.03 8.17 3.02 3.02 3.03 8.17 3.03 3.03 <th></th> <th>Fluor</th> <th>Target</th> <th>Content</th> <th>Treatment</th> <th>Cq</th> <th>Cq Mean</th> <th>Cq Std. Dev</th> <th>Delta Cq</th> <th>Cq</th> <th>Fold change</th> <th>-</th> <th></th> <th></th> <th></th> <th></th>		Fluor	Target	Content	Treatment	Cq	Cq Mean	Cq Std. Dev	Delta Cq	Cq	Fold change	-				
SYBR Kitele Unknown-14 Ipg 31.4 31.25 31.25 27.37 31.33 0.066 8.49 -3.37 10.34 SYBR Kitele Unknown-15 100pg 27.31 27.37 27.34 0.042 8.83 -3.03 8.17 3.03 8.17 3.03 8.17 3.03 8.17 <t< td=""><td></td><td></td><td></td><td>Unknown-13</td><td>Control</td><td>27.16 26.35</td><td>26.76</td><td>0.573</td><td>11.86</td><td>0</td><td>1.00</td><td></td><td></td><td></td><td></td><td></td></t<>				Unknown-13	Control	27.16 26.35	26.76	0.573	11.86	0	1.00					
SYBR Klotio Unknown-15 100pg 27.31 27.37 27.34 0.042 8.83 -3.03 8.17 Where the second secon				Unknown-14	Ipg	31.4	31.33	0,106	8.49	-3.37	10,34					
SYBR Klotio Lotio 27,37 27,49 0.064 9.66 -2.2 4.59 0 0 Unknown-16 Ing 27,63 27,44 27,49 0.064 9.66 -2.2 4.59 0 0 0 Unknown-17 100ng 29,66 29,68 0.021 10.91 -0.950 1.93 0 <t< td=""><td></td><td></td><td></td><td>Unknown-15</td><td>100pg</td><td>27.31</td><td>27.34</td><td>0.042</td><td>8.83</td><td>-3.03</td><td>8.17</td><td></td><td></td><td></td><td></td><td></td></t<>				Unknown-15	100pg	27.31	27.34	0.042	8.83	-3.03	8.17					
SYBR Artin Unknown-36 Unknown-3		SYBR	Klotho	11.1	10	27.37 27.53	97.40	0.074	0.66	2.2	1.20					
Unknown-17 100ng 29.69 29.68 0.021 10.91 -0.950 1.93 Image: Constraint of the second of the sec				Unknown-10	ing	27,44	27.49	0.004	9.00	-2.2	4.39				-	
Unknown-18 Iug 29.25 0.028 II.25 -0.610 1.53 Image: Symmetry of the second of t				Unknown-17	100ng	29.69	29.68	0.021	10.91	-0.950	1.93					
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$				Unknown-18	lug	29.23 29.27	29,25	0.028	11.25	-0.610	1.53					
Unknown-31 Unknown-32 19,11 10,07 0,007 Unknown-32 1pg 18,43 18,265 0,233 0				Unknown-31	Control	19.83	19.47	0.500								
Unknown-32 Ipg 18.1 18.265 0.233 Image: Control of the state of th		ł		Unknown-31 Unknown-32	control	19.11 18.43	12.17	0.007			-					
SYBR Actin Unknown-33 Unknown-34 Unknown-34 Unknown-34 Unknown-34 Unknown-35 Unknown-35 Unknown-36 Unknown-37 Unknown-38 Unknown-37 Unknown-38 Unknown-38 Unknown-38 Unknown-3		į.		Unknown-32	Ipg	18.1	18.265	0.233								
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			10	Unknown-33	100pg	18.68	18.51	0.240								
STEX Unknown-35 100ng 18.39 18.34 0.071 Unknown-35 Unknown-36 18.29 18.34 0.071 1000000000000000000000000000000000000		CVDD	X.C.	Unknown-34 Unknown-34	Ing	18.14	17.83	0.438			2					
Unknown-36 lug 18.46 0.057 Unknown-36 lug 18.38 0.057 No Template control NA NA NA No Template control NA NA NA No Template control NA NA NA		SIBK	Actin	Unknown-35 Unknown-35	100ng	18.39 18.29	18.34	0.071								
Onknown-so 16.38 No Template control NA No Template control NA No Template control NA				Unknown-36	lug	18.46	18.42	0.057								
No Template control				No Template control No Template control No Template control	NA	18.38 NA	NA	NA								
				No Template control				8								

J Cancer Sci Ther, an open access journal ISSN: 1948-5956

Target otho otho otho otho otho otho otho	Treatment Control	Ctrl	Expression	Expression SD	Corrected	Mean Cq	Cq SD					
otho otho otho otho otho otho	Control lpg				and the state of t		100000000					
otho otho otho otho otho	lpg	2.25	1.00	0.40	0.40	25.54	0.98					
otho otho otho otho		S S	0.97	0.17	0.17	26.75	0.52					
otho otho otho	100pg		2.04	0.05	0.05	26.27	0.00					
otho otho	Ing		1.82	0.00	0.00	26.96	0.00					
otho	100ng	; (g	2.36	0.34	0.34	25.64	0.00					_
	lug		6.36	2.26	2.26	25.46	1,03					_
day to a state of the state of	Control	*	51/ 5	NUA	31/4	17.25	0.61					-
ta actin	lng		N/A N/A	N/A N/A	N/A N/A	18.42	0,01					
ta actin	100ng		N/A	N/A	N/A N/A	19.01	0.01					-
ta actin	ing		N/A	N/A	N/A	19.53	0.00					
ta actin	100ng		N/A	N/A	N/A	18.59	0.42					
ta actin	lug	5	N/A	N/A	N/A	19.84	0.21					
						200410						
			107 Mar 105 Mar 10									
	Fluor	Target	Content	Sample	Melt Temp							
	SYBR	Klotho	Unknown	Control	83							_
	SYBR	Klotho	Unknown	Control	83.5	3						
	SYBR	Beta actin	Unknown	Control	17							D
	SYPP	Klotho	Unknown	las	81			Interfection	anfile of Woth of Cream ¹ # #	tip/Red) in Colo 36 cells		<u>ц</u>
	SYBR	Klotho	Unknown	Ing	83.5			Anthrocange	A A International Contraction			_
	SYBR	Klotho	Unknown	lpe	77	200 1						
	SYBR	Beta actin	Unknown	lpg	77			1				
	SYBR	Klothe	Unknown	100pg	83.5	1					1	-
	SYBR	Klotho	Unknown	100pg	83	1600 \$						nii e
	SYBR	Beta actin	Unknown	100pg	77.5			4. +				
	SYBR	Beta actin	Unknown	100pg	77	Į		1		/		
1	SYBR	Klotho	Unknown	lng	84					i sai famani	the second second	
	SYBR	Klotho	Unknown	Ing	84			1			1	
	SYBR	Beta actin	Unknown	lng	78					1	1	
3	SYBR	Beta actin	Unknown	lng	77	600						
	SYBR	Klotho	Unknown	100ng	83	- 1		1	/	11	-	-
	SYBR	Riotho	Unknown	Toong	2.26	— İ		2010 2010 2010				
	SVBP	Beta actin	Unknown	100ng	77	- 0+ 🐌						
	SYBR	Klotho	Unknown	lue	84	- 12	/	11	1		1	-
	SYBR	Klotho	Unknown	lug	83.5	-						_
	SYBR	Beta actin	Unknown	lug	77	•		10	20		30 40	
	SYBR	Beta actin	Unknown	lug	77	-			Cycle	K.		-
2	SYBR	Klotho	No Template Control		NA				<u>Ц</u>			
	SYBR	Klotho	No Template Control		NA							
	SYBR	Beta actin	Unknown		NA							
	SYBR	Beta actin	Unknown		NA							
			· · · · · ·		Manual	calculated data	format		Dalta Dalta			
	Fluor	Target	Content	Sample	Cq	Cq Mean	Cq Std. Dev	Delta Cq	Cq	Fold change		
			Unknown-07	Control	24.84 26.23	25.54	0.000	8.29	0	1.00		
			Unknown-08	lpg	26.39	26.76	0.516	8.33	0.04000000000	0.97		
	SYBR	Klothe	Unknown-15	100pg	25.56	26.27	1.252	7.26	-1.03	2.04	-	
			Unknown-10	lng	25.92	26.96	1.464	7.43	-0.859999999999	1.82		
			Unknown-11	100ng	24.64 26.19	25.64	1.407	7.05	-1.24	2.36		
			Unknown-12	lug	24.74	25.47	1.025	5.62	-2.67	0. JO		_
			Unknown-31	Control	16.82	17.25	0.608					
			Unknown-31	C. Soliton	17.68	. etcer	0.000					_
			Unknown-32	los	18.43	18.43	0.007					
			Unknown-32	10	18.42							
			Unknown-33	100pg	19.06	19.01	0.078					
			Unknown-33		18.95	10.52	State of the second state					-
		11/11/19	Unknown-34	lng	19.99	17.55	0.651					-
-	SYBR	Actin	Unknown-34		19.07	18.60						-
			Unknown-35	100ng	18.3	18.00	0.417					
			Unknown-36	1	10.09	19.94	and and a second se					-
			Unknown-36	lug	19.69	12.09	0.212					-
			No Tomolate Control		NA		7					-
			The second		13/4	11						
			No Template Control	122.5.	NA	1 832	10.00					
			No Template Control No Template Control	NA	NA NA	NA	NA				-	

Figure 8: Raw data COLO-205 cell line.

Results

Three different cell lines were individually treated with Metadichol at various concentrations to assess the expression of Klotho gene. The maximum up regulation of Klotho gene expression is seen at lowest concentration treated, i.e., 1pg/ml in both MIAPACA and PANC-1 cells up 10.34 and 3.66-fold, whereas, in COLO 205 the expression at 1µg/ml was maximum up 6.36-fold compared to control. Overall, the Up regulation of Klotho gene expression level is dose dependent in MIAPACA cells from highest to lowest treatment concentrations from 1µg/ml to 1pg/ml.

					CFX96 softwar	e calculated dat	a format						
Target	Sample	Ctrl	Expression	Expression SD	Corrected Expression SD	Mean Cq	Cq SD						
Klothe	Control	+	1.000	0.054	0.054	27.36	0.279		-				
Klotho	lpg	1	3.655	0.030	0.030	26.67	0.000						
Klotho	100pg		2.173	0.365	0.365	26.32	0.699		1				
Klotho	lng		2.042	0.181	0.181	27.15	0.052						
Klotho	100ng		1.094	0.187	0.187	27.97	0.679						
Klotho	lug		1.385	0.136	0.136	27.04	0.512						-
Actin	Control	*	N/A	N/A	N/A	17.21	0.05		-				
Actin	lpg	1925	N/A	N/A	N/A	18.39	0.04						
Actin	100pg		N/A	N/A	N/A	17.29	0.54						
Actin	Ing	[]	N/A	N/A	N/A	18.03	0.46						-
Actin	100ng		N/A	N/A	N/A	17.95	0.58						
Actin	lug		N/A	N/A	N/A	17.36	0.09		-				_
	Fluor	Target	Content	Sample	Melt Temp				1				
	SYBR	Klotho	Unknown-07	Control	76.5								
	SYBR	Actin	Unknown-25	Control	77								
	SYBR	Actin	Unknown-25	Control	77		Amplification	Profile of Klo	tho(Green)&	Actin(Red) in	Panc-1 cell lin	e	
	SYBR	Klotha	Unknown-08	Ipg	76.5	2000							
	SYBR	Actin	Unknown-26	Ing	77				1		:		
	SYBR	Actin	Unknown-26	Ing	77	t		1			-		
	SYBR	Klotho	Unknown-15	100pg	76.5	1500		• • • • • • • • • • • •				· · · · · · · · · · · ·	
	SYBR	Klotho	Unknown-15	100pg	76.5	Ŧ		1	1	/			
	SYBR	Actin	Unknown-27	100pg	77	7 4000		and second	ana da sa	/		17	
	SYBR	Actin	Unknown-27	100pg	77	E 1000 T				1		112	
	SYBR	Klotho	Unknown-10	Ing	77	Ŧ				1 11	1	4	
	SYBR	Actin	Unknown-10	Ing	77	500				la f fan		·	
	SYBR	Actin	Unknown-28	Ing	77	1		-	/		111	/: 1	
	SYBR	Klotho	Unknown-11	100ng	76.5	1	-			<u></u>	://	<u></u> : :	
	SYBR	Klotho	Unknown-11	100ng	76.5	0	-	1			1 /		
	SYBR	Actin	Unknown-29	100ng	77	ŧ			· · · ·		$1 \rightarrow 1 \rightarrow 1$		
	SYBR	Actin	Unknown-29	100ng	77	0		10	20		30	40	
	SYBR.	Klotho	Unknown-12	lug	76.5				Cycle	15			
	SYBR	Klotho	Unknown-12 Unknown 20	lug	77								
	SYBR	Actin	Unknown-30	lug	77.5				-				
-	SYBR	Klotho	No Template Control	Tug	NA								
	SYBR	Klotho	No Template Control	S	NA								
	SYBR	Actin	No Template Control		NA								
	SYBR.	Actin	No Template Control	3	NA								
	SYBR	Actin	No Template Control		NA				-				-
					Manual	as low latest data	. Comment	-					1
	Fluor	Target	Content	Sample	Ca	Co Mean	Co Std. Dev	Delta Co	Delta Delta	Fold change			
			Linkson 07	Control	27.26	07.24	0.000	10.16	Cq	1.00			_
			Unknown-07	Control	27.50	2/,50	0,000	10.15	0	1.00			
	1		Unknown-08	lpg	26.66	26.67	0.007	8.28	-1.87	3.66			
			Unknown-15	100pg	26.8 25.83	26.32	0.686	9.03	-1.12	2.17	-		
	SYBR	Klotho	Unknown-10	Ing	27.12 27.18	27.15	0.042	9.12	-1.03	2.04	75		
			Unknown-11	100ng	27.49 28.45	27.97	0.679	10.02	-0.130000000000	1.09			1
			Unknown-12	lug	27.41 26.67	27.04	0.523	9.68	-0.470000000000	1.39	-		-
	<u> </u>		Linknown 21	8 5	17.25				-				-
	1		Unknown-31	Control	17.18	17.22	0.049						
	1		Unknown-32		18.42	18.39							-
	1		Unknown-32	Ipg	18.36		0.042						
			Unknown-33	100mg	16.91	17.30	0.544						
			Unknown-33	ToohR	17.68		0.0440						
			Unknown-34	Ing	17.7	18.03	0.467						
	SYBR	Actin	Unknown-34		18.36	17.07							
	(1.000) (1.000) (1.000)		Unknown-35	100ng	17.54	17.95	0.580		-				
			Unknown-35		18.30	17.24							
	1		Unknown-36	lug	17.29	17.30	0.092						
()	1		No Template Control		NA								+
	1		No Template Control		NA								
			No Template Control	NA	NA	NA	NA						
			No Template Control		NA								
				12.0	P.62		1						

Figure 9: Raw data PANC1 cell line.



Discussion

King have identified small molecules that elevated Klotho expression, but the increase was only in the range of 20-50% at micro molar (uM) concentrations and with compounds whose toxicity is not known in humans [20].

Marco [21] suggested that Orally-available, transcriptional factors like D-alpha-tocopherol [22], and vitamin D receptors (VDR) agonists such as cholecalciferol [23,24] and lithocholic acid [25] can increase Klotho expression. They suggested that, or a combination of these molecules would result in increased expression of endogenous, human Klotho through transcriptional activation.

R.E. Forster [26] have postulated that the liganded VDR up regulates Klotho gene *via* Vitamin D response elements (VDRE). The actions of 1,25 dihydroxyvitamin D3 (1,25 D3) on phosphorus are opposed *via* the combined effects of FGF23 and Klotho, which is up regulated by the liganded vitamin D receptor.

1,25D3 acting on VDR induces FGF23 in osteocytes to increase circulating FGF23 [27], which protects against hyperphosphatemia [28]. FGF23 also increases 1,25D3 degradation [29].

Metadichol^{*} a nanoemulsion of long-chain binds to VDR Receptor as an inverse agonist, and the formulation contains D-alpha-tocopherol [30]. Inverse agonists bind to the same binding site as the agonists in case of VDR it is 1,25 dihydroxy Vitamin D3. They induce a pharmacological response different and distinct when compared to that of the agonist. Metadichol in our human subjects [31] behaves more likely a Protean agonist as it exhibits dual properties like, e.g. Increasing Insulin Secretion (type 1) and reducing Insulin (type 2). Protean agonists behave as both positive and negative agonists on the same receptor, depending on the degree of constitutive activity. If there is no constitutive activity, the agonist would be a positive agonist [32]. When constitutive activity is present, the Protean agonist would be an inverse agonist. Metadichol an extract of sugar cane wax exhibits properties that could also be considered as an Adaptogens [33] which are unique in their ability to balance endocrine hormones and the immune system [34-37]. Adaptogens help maintain optimal homeostasis in the body. Adaptogens are proposed to have a normalizing in the body effect on the body and have the ability to toning down the activity of hyper functioning systems in case of constitutive receptors or strengthening the operation of hypo-functioning systems like an agonist. Given the precedence of VDR and its role in regulating Klotho genes it is not surprising that Metadichol* actions on VDR have a similar outcome and as a hormone, it shows activity at picogram levels. Also, Metadichol is nontoxic [38-40] as compared to other solutions in literature to enhance the use of Klotho as a therapeutic target.

Conclusion

Klotho has been shown to have a wide range of roles in many pathologies. Changes in the levels of Klotho are associated with many diseases. It could be useful as a potential biomarker. However, also has a future as a safe therapeutic in mitigating various diseases where Klotho has a significant role (41).

References

- Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, et al. (1997) Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature 390: 45-51.
- 2. Kuro-o M (2010) Klotho. Pflugers Arch 459: 333-343.
- Haussler MR, Haussler CA, Whitfield GK, Hsieh JC, Thompson PD, et al. (2010) The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthy aging. J Steroid Biochem Mol Biol 121: 88-97.
- Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518.

- Zhou X, Wang X (2014) Klotho: A novel biomarker for cancer. J Cancer Res Clin Oncol 141: 961-969.
- Kurosu H, Kuro OM (2009) The klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 299: 72-78.
- Chen CD, Li H, Liang J, Hixson K, Zeldich E, et al. (2014) The anti-aging and tumor suppressor protein klotho enhances differentiation of a human oligodendrocytic hybrid cell line. J Mol Neurosci 55: 76-90.
- Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, et al. (2009) Functional variant of klotho: A breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene 29: 26-33.
- 9. Zhang H, Li Y, Fan Y, Wu J, Zhao B, et al. (2008) Klotho is a target gene of PPAR-gamma. Kidney Int 74: 732-739.
- Forster RE, Jurutka PW, Hsieh JC, Haussler CA, Lowmiller CL, et al. (2011) Vitamin D receptor controls the expression of the anti-aging klotho gene in mouse and human renal cells. Biochem Biophys Res Commun 414: 557-562.
- Hsu SC, Huang SM, Lin SH, Ka SM, Chen A, et al. (2014) Testosterone increases renal anti-aging klotho gene expression *via* the androgen receptormediated pathway. Biochem J 464: 221-229.
- Hsu SC, Huang SM, Chen A, Sun CY, Lin SH, et al. (2014) Resveratrol increases anti-aging Klotho gene expression via the activating transcription factor 3/c- Jun complex-mediated signaling pathway. Int J Biochem Cell Biol 53: 361-371.
- Sopjani M (2014) Relevance of the aging suppressor protein Klotho in health and disease: Introduction, cellular signaling, mechanisms, clinical relevance, conclusions, and perspectives. Lap Lambert Academic Publishing 2: 1.
- 14. Tang X, Wang Y, Fan Z, Ji G, Wang M, et al. (2016) Klotho: A tumor suppressor and modulator of the Wnt/β-catenin pathway in human hepatocellular carcinoma. Lab Invest 96: 197-205.
- Ligumsky H, Rubinek T, Merenbakh-Lamin K, Yeheskel A, Sertchook R, et al. (2015) Tumor suppressor activity of klotho in breast cancer is revealed by structure-function analysis. Mol Cancer Res 13: 1398-1407.
- Wang Y, Chen L, Huang G, He D, He J, et al. (2013) Klotho sensitizes human lung cancer cell line to cisplatin *via* PI3k/Akt pathway. PLOS One 8: e57391.
- Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, et al. (2012) KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-1 signaling in pancreatic cancer. Clin Cancer Res 17: 4254-4266.
- Xie B, Zhou J, Shu G, Liu DC, Zhou J, et al. (2013) Restoration of klotho gene expression induces apoptosis and autophagy in gastric cancer cells: tumor suppressive role of klotho in gastric cancer. Cancer Cell Int 13: 18.
- Doi S, Zou Y, Togao O, Pastor JV, John GB, et al. (2011) Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 286: 8655-8665.
- King GD, Chen C, Huang MM, Zeldich E, Brazee PL, et al. (2012) Identification of novel small molecules that elevate Klotho expression. Biochem J 441: 453-461.
- 21. Marco R (2017) A novel approach to klotho aimed at delaying and reversing aging. BAOJ HIV 3: 029.
- Xuan NT, Trang PT, Phong NV, Toan NL, Trung DM, et al. (2016) Klotho sensitive regulation of dendritic cell functions by vitamin E. Biol Res 49: 45.

- Haussler MR, Whitfield GK, Haussler CA, Sabir MS, Khan Z, et al. (2016) 1, 25-Dihydroxyvitamin D and Klotho: A tale of two renal hormones coming of age. Vitam Horm 100: 165-230.
- 24. Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro OM, et al. (2012) Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 82: 1261-1270.
- Kollitz EM, Zhang G, Hawkins MB, Whitfield GK, Reif DM, et al. (2016) Evolutionary and functional diversification of the vitamin D receptor-Lithocholic acid partnership. PLoS ONE 11: e0168278.
- Forster RE, Jurutka PW, Hsieh JC, Haussler CA, Lowmiller CL, et al. (2011) Vitamin D receptor controls expression of the anti-aging klotho gene in mouse and human renal cells. Biochem Biophys Res Commun 414: 557-562.
- 27. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, et al. (2005) 1 alpha, 25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: The final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042.
- Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M, et al. (2011) Regulation of serum 1, 25 (OH)₂ Vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol 301: F371-377.
- 29. Raghavan PR (2014) U.S Patent 8,722,093
- 30. Raghavan PR (2015) U.S Patent 9,006,292
- 31. Neubig RR (2007) Missing links: Mechanisms of protean agonism. Mol Pharmacol 71: 200-1202.
- Panossian A, Wikman G (2009) Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity. Current Clin Pharmacol 4: 198-219.
- Raghavan PR (2017) Metadichol: A novel ROR gamma inverse agonist and its applications in psoriasis. J Clin Exp Dermatol Res 8: 433.
- Raghavan PR (2017) Metadichol[®] and vitamin C increase *in vivo*, an open-label study. Vitam Miner 6: 163.
- 35. Raghavan PR (2017) Rheumatoid arthritis and osteoporosis: A case study. J Arthritis 6: 240.
- Raghavan PR (2017) Systolic and diastolic BP control in metabolic syndrome patients with Metadichol[®] a novel nano emulsion lipid. J Cardiol & Cardiovasc Ther 5: 555660.
- Alemán CL, Más R, Hernández C, Rodeiro I, Cerejido E, et al. (1994) A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol Lett 70: 77-87.
- Alemán CL, Más Ferreiro R, Noa Puig M, Rodeiro Guerra I, Hernández Ortega C, et al. (1994) Carcinogenicity of policosanol in Sprague-Dawley rats: A 24-month study. Teratog Carcinog Mutagen 14: 239-249.
- Alemán CL, Puig MN, Elías EC, Ortega CH, Guerra IR, et al. (1995) Carcinogenicity of policosanol in mice: An 18-month study. Food Chem Toxicol 33: 573-578.
- Georgiou A, Lisacek-Kiosoglous A, Yiallouris A, Stephanou A, Patrikios I (2017) Klotho: The protein of faith. EC Neurology 75: 189-223.